Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 7/20 | 0.33 |
| ▸ | MMP2 | P08253 | 7/20 | 0.33 |
| ▸ | CA12 | O43570 | 6/20 | 0.33 |
| ▸ | CA1 | P00915 | 6/20 | 0.33 |
| ▸ | CA9 | Q16790 | 6/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | SLC9A3 | P48764 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1799336 | 0.93 | F2 (0.34) | CA2CA12CA1CA9ALDH1A1 | |
| SCHEMBL3874559 | 0.92 | NPY4R (0.36) | SLC9A3 | |
| SCHEMBL4372334 | 0.92 | LTA4H (0.40) | LTA4HMMP2MMP9MMP14MMP13 | |
| SCHEMBL1800587 | 0.91 | SLC9A3 (0.33) | CA2CA12CA1CA9SLC9A3 | |
| SCHEMBL1799060 | 0.91 | SLC9A3 (0.36) | MMP2SLC9A3MMP9MMP14MMP12 | |
| SCHEMBL1800732 | 0.90 | MAP2K1 (0.33) | CA2CA12CA1CA9 | |
| SCHEMBL4371687 | 0.89 | SMN1; SMN2 (0.36) | LTA4HEGLN2CA2MMP2CA12 | |
| SCHEMBL4375791 | 0.87 | MMP2 (0.42) | LTA4HEGLN2CA2MMP2CA12 | |
| SCHEMBL4370906 | 0.82 | SCN9A (0.36) | CA2CA12CA1CA9ALDH1A1 | |
| SCHEMBL4377327 | 0.82 | F2 (0.39) | CA2MMP2CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247451-B2 | ADAM10 and its uses related to infection | VANDERBILT UNIVERSITY (US) | 2012-08-21 | — | — | US | claimed |
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | VANDERBILT UNIVERSITY | 2009-09-03 | — | — | US | claimed |
| EP-1461313-B1 | HUMAN ADAM-10 INHIBITORS | EXELIXIS INC (US) | 2009-08-05 | — | — | EP | claimed |
| EP-1461313-B1 | HUMAN ADAM-10 INHIBITORS | EXELIXIS INC (US) | 2009-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | ADAM10, ADAM12, ADAM17 | LTA4H 1842/4885EGLN2 3526/4885CA2 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.